Alpha Tau Medical Ltd. Ordinary Shares (DRTS)
Stock · NASDAQ · Health Care
$12.31as of 10/16/2026
Price chart
Active signals
DRTS Signal Track Record
How signals performed across all stocks →What DRTS's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 51 | +0.4% | 53% | June 30, 2026 |
| Bollinger Band Breakout | 25 | -2.7% | 48% | September 17, 2026 |
| Bollinger Band BreakdownActive now | 16 | +3.6% | 63% | July 28, 2026 |
| 200-Day Moving Average TouchActive now | 13 | 0.0% | 46% | July 29, 2025 |
| Any 20-session window (baseline) | +0.4% | 51% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About DRTS
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors…
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Employees
- 121
- Website
- www.alphatau.com/
Fundamentals
- 1-day range
- $12.66$13.3
- Market cap
- $1.14B
- P/E (trailing)
- —
- P/E (forward)
- -23.72
- EPS (trailing)
- $-0.66
- Dividend yield
- —
- Beta
- 1.26
- Avg. volume
- 554.0K
Forecasts
5 analyst ratings
Alpha Tau Medical Ltd. Ordinary Shares Competitors
Chosen by industry and closest market cap.
- DRTSAlpha Tau Medical Ltd. Ordinary Shares$12.29▼ 6.61%Market cap $1.14BP/E —$3.43$15.79
- PRCTPROCEPT BioRobotics Corporation Common Stock$17.57▼ 3.20%Market cap $1.14BP/E —$16.67$38.11
- IRMDiRadimed Corporation Common Stock$88.27▼ 1.23%Market cap $1.17BP/E 49.82$71.34$107.9
- BVSBioventus Inc. Class A Common Stock$13.3▼ 3.69%Market cap $1.17BP/E 21.32$6.46$15.89
- TNDMTandem Diabetes Care Inc. Common Stock$16.24▼ 1.69%Market cap $1.29BP/E —$12.26$29.65
- AORTArtivion Inc. Common Stock$21.78▼ 0.41%Market cap $1.29BP/E 117.64$19.16$48.25
- IARTIntegra LifeSciences Holdings Corporation Common Stock$13.21▼ 2.37%Market cap $1.33BP/E —$8.7$20.49
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| DRTS Alpha Tau Medical Ltd. Ordinary Shares | $1.14B | — | $12.29 | ▼ 6.61% | $3.43$15.79 |
| PRCT PROCEPT BioRobotics Corporation Common Stock | $1.14B | — | $17.57 | ▼ 3.20% | $16.67$38.11 |
| IRMD iRadimed Corporation Common Stock | $1.17B | 49.82 | $88.27 | ▼ 1.23% | $71.34$107.9 |
| BVS Bioventus Inc. Class A Common Stock | $1.17B | 21.32 | $13.3 | ▼ 3.69% | $6.46$15.89 |
| TNDM Tandem Diabetes Care Inc. Common Stock | $1.29B | — | $16.24 | ▼ 1.69% | $12.26$29.65 |
| AORT Artivion Inc. Common Stock | $1.29B | 117.64 | $21.78 | ▼ 0.41% | $19.16$48.25 |
| IART Integra LifeSciences Holdings Corporation Common Stock | $1.33B | — | $13.21 | ▼ 2.37% | $8.7$20.49 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Oramed Pharmaceuticals: Hold Reiterated As Alpha Tau Investment Delivers And MoreSeekingAlpha · 9/11/2026
Insider Activity
Insider Actions →- Levy Raphi · August 21, 2026 · Sale2.9K @ $15
- Levy Raphi · August 21, 2026 · Option Exercise2.9K @ $2.98
- Levy Raphi · August 11, 2026 · Sale17.7K @ $14
- Levy Raphi · August 11, 2026 · Option Exercise17.7K @ $2.98
- Levy Raphi · July 6, 2026 · Sale2.3K @ $14
- Levy Raphi · July 6, 2026 · Option Exercise2.3K @ $2.98
- Levy Raphi · July 2, 2026 · Sale17.9K @ $13
- Levy Raphi · July 2, 2026 · Option Exercise17.9K @ $2.98
- Levy Raphi · July 1, 2026 · Sale2.1K @ $13.02
- Levy Raphi · July 1, 2026 · Option Exercise2.1K @ $2.98
- Levy Raphi · June 30, 2026 · Sale20.0K @ $12
- Levy Raphi · June 25, 2026 · Sale15.8K @ $11
- Levy Raphi · June 25, 2026 · Sale4.2K @ $11
- Levy Raphi · June 23, 2026 · Sale2.5K @ $10
- Levy Raphi · June 23, 2026 · Sale15.0K @ $9.47
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
Alpha Tau Medical Gains Analyst Support as GBM Treatment Shows Promise
Alpha Tau Medical is drawing increased attention from analysts as the company approaches year-end with potential breakthrough data for its Alpha DaRT treatment in glioblastoma. Barclays raised its price target to $30, notably above the current analyst consensus of $14.40. Separately, Alpha Tau completed enrollment for its pancreatic cancer pilot study, suggesting progress across its clinical pipeline. The company is also scheduled to present at major investor conferences in September.
Alpha Tau Medical Gains Analyst Support as GBM Treatment Shows Promise. Alpha Tau Medical is drawing increased attention from analysts as the company approaches year-end with potential breakthrough data for its Alpha DaRT treatment in glioblastoma. Barclays raised its price target to $30, notably above the current analyst consensus of $14.40. Separately, Alpha Tau completed enrollment for its pancreatic cancer pilot study, suggesting progress across its clinical pipeline. The company is also scheduled to present at major investor conferences in September.